TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06374966

Intervention type: DRUG
Intervention: Zonisamide
Description: This is a real-world study，so we prospectively enrolled patients with focal epilepsy suitable for taking zonisamide as an add-on medication
Study: NCT04697862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FiO2 15%) under Sildenafil
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FiO2 15%)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Study: NCT05165979

Intervention type: OTHER
Intervention: Hospitalization due to COVID-19
Description: Hospitalization due to COVID-19
Study: NCT06433479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
Description: Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
Study: NCT05495581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous
Study: NCT05993741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR Dental Care Training System
Description: AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR Dental Care Training System
Description: AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
Study: NCT04596644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Investigates two strengths of cannabis.
Study: NCT05293340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avocado Vouchers
Description: Food as Medicine to demonstrate clinically meaningful benefits for underserved communities. Avocados are fruits with fats, fiber, micronutrients, and bioactive phytochemicals.
Study: NCT05296837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 40 MG ( 20mg twice daily)
Description: Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 200 MG ( 100 mg twice daily)
Description: 200 mg dose doxycycline to be administered as 100mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered in tablet form twice daily
Study: NCT05035238

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple dose vaccination by inactivated Covid19 vaccine
Description: triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple dose vaccination by inactivated Covid19 vaccine
Description: triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.
Study: NCT04481672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
Study: NCT05517564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-60106
Description: The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-to-match GM-60106 capsules
Study: NCT06214533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.
Study: NCT05709483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
Study: NCT05947838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circulating tumoral DNA directed neoadjuvant therapy arm
Description: Given by IV (vein)
Study: NCT04940728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative thinking techniques intervention program
Description: The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
Study: NCT04141319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30ml of local infiltration solution containing 60mg ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30ml of local infiltration solution containing 6mg ketorolac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30ml of local infiltration solution containing 6mg ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 30ml of local infiltration solution containing 0.1mg epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Study: NCT05958589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal block with levobupivacaine
Description: After the introduction of general anesthesia, a single shot caudal block will be performed with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernioplasty
Description: Elective inguinal hernioplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal hernioplasty
Description: Elective inguinal hernioplasty
Study: NCT06001840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion factors
Description: In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion factors
Description: In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mitigation strategies
Description: Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mitigation strategies
Description: Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record).
Study: NCT04752722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-70 (phase 1)
Description: Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-70 (phase 2)
Description: Cohort 1 and Cohort 2: Patients will receive up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks.
Study: NCT06493734

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: SBRT will be delivered in 15 fractions of 4 to 4.5Gy (risk-adapted), one fraction each weekday for 3 weeks.
Study: NCT06341400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DisitamabVedotinForIicction Toripalimab
Description: Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
Study: NCT05670912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wei Li Bai capsules
Description: The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator of Wei Li Bai capsules
Description: The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
Study: NCT05430711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
Study: NCT04875403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle trainning
Description: linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
Study: NCT05521100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular closure device
Description: Suture of lower extremity veins using the Proglide Vascular Closure Device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: figure eight stitch
Description: Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
Study: NCT04511442

Intervention type: OTHER
Intervention: Evaluation of food preferences during a standardized and validated buffet.
Description: The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~* high / low in fat (HF / LF)~* high / low in carbohydrates (HC / LC)~* high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants.

Intervention type: OTHER
Intervention: Evaluation of food preferences during a standardized and validated buffet.
Description: The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~* high / low in fat (HF / LF)~* high / low in carbohydrates (HC / LC)~* high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants.
Study: NCT05946759

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Histolog Scanner
Description: The PMPF study is collecting data that includes the use of the CE Mark IVD Histolog Scanner for the breast lumpectomy margin assessment.
Study: NCT04761705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JV-GL1
Description: Experimental Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JV-GL1
Description: Experimental Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: Active Control
Study: NCT04757701

Intervention type: OTHER
Intervention: Social Behavioral surveys, interviews, and focus groups
Description: Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.

Intervention type: OTHER
Intervention: Social Behavioral surveys, interviews, and focus groups
Description: Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.
Study: NCT06296654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment-Based Interventions
Description: The Empowerment-Based Interventions was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group d

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Health Education
Description: Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
Study: NCT05701137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR-RTE
Description: The experimental group will have EMDR recent traumatic event.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: The comparator group will have usual psychological intervention.
Study: NCT06088849

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venipuncture
Description: The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
Study: NCT04735458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
Description: After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
Study: NCT06562842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular exercise
Description: Participants will perform regular exercise training for 12 weeks, followed by 4 weeks of detraining.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular exercise
Description: Participants will perform regular exercise training for 12 weeks, followed by 4 weeks of detraining.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular exercise
Description: Participants will perform regular exercise training for 12 weeks, followed by 4 weeks of detraining.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control comparator
Description: Participants will remain sedentary throughout the 16-weeks intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control comparator
Description: Participants will remain sedentary throughout the 16-weeks intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control comparator
Description: Participants will remain sedentary throughout the 16-weeks intervention period.